Products in Development
Bioniche has developed a technology for the treatment of human cancers. The first product developed from this technology is Urocidin™, a formulation of Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) suspension, previously known as MCC suspension, for the treatment of human bladder cancer. The terminology change from MCC to MCNA was due to further characterization of MCC suspension that was carried out based on regulatory feedback. This led to the discovery that the current method of manufacture resulted in a cell wall composition whereby the RNA, in addition to the earlier recognized DNA, were conserved and active, hence the name MCNA.
One Phase III clinical trial has been completed using Urocidin™. For the second Phase III trial, the subject population in the study was originally planned to include approximately 450 subjects with carcinoma in situ (CIS) and/or high grade papillary tumors who had failed prior treatment with BCG (refractory or recurrent). The study was initiated in October, 2010 and recruitment activities were terminated on November 2, 2012 due to logistical issues related to the study design, including slow recruitment.
For more information about the Company’s clinical programs, please contact Bioniche Therapeutics at firstname.lastname@example.org
Animal Health Products
Information about Bioniche Animal Health products can be found at www.bionicheanimalhealth.com
One Health Products
Econiche™ is the first marketed product of the Bioniche One Health division.
Contact Bioniche One Health